Navigation Links
Diatos Announces Positive Clinical Results for its DTS-201,Doxorubicin Prodrug Program

the tumor site, avoiding systemic side effects. DTS-301 is in Phase II clinical studies and was in-licensed from Protherics PLC (LSE: PTI / NASDAQ: PTIL).

-- DTS-201, a doxorubicin prodrug, increases the concentration of doxorubicin, a widely used cancer drug, at the tumor site by means of a reactivation mechanism specific to the tumor environment. DTS-201 has completed Phase I clinical studies in Belgium and France in Q2-07. Exclusive European rights for DTS-201 were in-licensed from Medarex Inc.

-- DTS-108 is a prodrug of SN-38, the active metabolite of the widely-used cancer drug irinotecan, and is based on Diatos' Vectocell(R) technology. DTS-108 aims to increase the efficacy of SN-38 while reducing the toxic effects of irinotecan. DTS-108 is in preclinical development.

For more information on Diatos, please visit www.diatos.com.

The Diatos logo and Vectocell(R) are registered trademarks of Diatos SA.

Contact

Diatos SA
General enquiries
Dr John Tchelingerian, PhD, President & CEO
c/o Virginie Leplat
Director of Human Resources & Administration
Tel.: +33 (0)1 53 80 93 80
vleplat@diatos.com
or
c/o Guillaume Dussert, Associate BD & Marketing Manager
Tel.: +33-(0)1 53 80 93 83
gdussert@diatos.com
or
Medical enquiries
Dr Jamal Gasmi, MD, MSc
Chief Medical Officer
Head of Clinical Development & Regulatory Affairs
Tel.: +33 (0)1 53 80 93 53
jgasmi@diatos.com
or
Press contacts
Northbank Communications
Justine Lamond, +44 (0)20 7268 3242





Page: 1 2 3 4 5

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:7/28/2014)... , July 28, 2014  TNI BioTech, Inc. ... company focused on the development, marketing and distribution ... filed definitive proxy materials with the Securities and ... Meeting of Shareholders to be held on Thursday, ... Time. The record date for determining those shareholders ...
(Date:7/28/2014)... 2014  ResMed (NYSE: RMD ), an ... of sleep-disordered breathing and other chronic respiratory conditions, has ... against Taiwanese medical device manufacturer APEX Medical Corp. ... WiZARD 210 and 220 masks.  The judgment was entered ... , is appealable, and applies throughout Germany.  ...
(Date:7/28/2014)...  ANI Pharmaceuticals, Inc. (NASDAQ: ANIP ) ... second quarter and year-to-date 2014 financial results on Monday, ... financial markets. The earnings press release will be accessible ... www.anipharmaceuticals.com . Arthur S. Przybyl ... C. Arnold , Vice President and Chief Financial Officer, ...
Breaking Medicine Technology:TNI BioTech, Inc., Files Definitive Proxy Materials; Mails Letter Urging Shareholders to Vote the Proxy Card 2TNI BioTech, Inc., Files Definitive Proxy Materials; Mails Letter Urging Shareholders to Vote the Proxy Card 3ResMed Receives Permanent Injunction against APEX in Germany, Continues Enforcement of Patents in Europe 2ANI Pharmaceuticals Schedules Conference Call for Second Quarter 2014 Financial Results 2
... Researchers to save and organize content for mobile ... a world-leading provider of scientific, technical and medical information products ... RACK app on SciVerse Applications . Developed by ... users to save PDFs of interest in SciVerse for further ...
... 14, 2011  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ... drugs to its development pipeline, ISIS-APOARx, ISIS-DGAT2Rx and ISIS-FVIIRx.  ... at 12:00 p.m. Eastern Time to provide more detail ... has been an extremely successful year for Isis and ...
Cached Medicine Technology:Amphetamobile Develops AMMO RACK App for SciVerse Applications 2Amphetamobile Develops AMMO RACK App for SciVerse Applications 3Amphetamobile Develops AMMO RACK App for SciVerse Applications 4Isis Adds Three New Drugs to Its Development Pipeline 2Isis Adds Three New Drugs to Its Development Pipeline 3Isis Adds Three New Drugs to Its Development Pipeline 4Isis Adds Three New Drugs to Its Development Pipeline 5
(Date:7/28/2014)... (PRWEB) July 29, 2014 A leading ... Social Security disability trust fund by reallocating payroll taxes ... new poll by The Senior Citizens League (TSCL) ... said shifting revenues from the Social Security retirement trust ... to fix the disability program’s financing. “TSCL believes this ...
(Date:7/28/2014)... 2014 The “Tissue Diagnostics ... Digital pathology & Workflow, Special Staining), Disease ... Non Small Cell Lung Cancer and Others), ... companies, Research Laboratories, Contract Research Organizations and ... BRIC, Japan & RoW) - Trends & ...
(Date:7/28/2014)... July 28, 2014 A January ... of gluten intake in those who were self-diagnosed gluten-intolerant ... director of nutrition for San Diego health and wellness ... gluten considerations for those who are unclear about the ... that gluten is a protein, found in wheat, barley, ...
(Date:7/28/2014)... Dotinga HealthDay Reporter MONDAY, ... humans just milliseconds to look at someone,s face and judge ... finds that certain facial features seem to trigger specific first ... size of the mouth, for example, appear directly linked to ... attractiveness. The study findings suggest that first impressions ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Shofner ... Operation Military June . Renowned LASIK and Cataract ... to provide significant funds and public awareness for ... retired military personnel and their families. “This was ... proudly give nearly $5,000 to a variety of ...
Breaking Medicine News(10 mins):Health News:The Senior Citizens League Finds No Support Among Seniors for Likely Disability Trust Fund Fix 2Health News:The Senior Citizens League Finds No Support Among Seniors for Likely Disability Trust Fund Fix 3Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 2Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 3Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 4Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 5Health News:VeraVia Explains the Basics of Gluten-Intolerance Following Industry Study 2Health News:VeraVia Explains the Basics of Gluten-Intolerance Following Industry Study 3Health News:Facial Dimensions May Be Key to First Impressions 2Health News:Facial Dimensions May Be Key to First Impressions 3Health News:Shofner Vision Center’s “Operation Military June” Provided Funds For Local Not-For-Profit Organizations Supporting Military And Their Families 2Health News:Shofner Vision Center’s “Operation Military June” Provided Funds For Local Not-For-Profit Organizations Supporting Military And Their Families 3
... vegetables to one,s diet may help decrease the chance of ... vegetables may decrease the risk of squamous cell lung cancer, ... Cancer Epidemiology, Biomarkers & Prevention , a journal of ... smoking is the most important preventive action in reducing lung ...
... nearly every discussion, debate or lawsuit about gay marriage, the ... gay couples make for good parents? Will their children ... brought in from a pre-existing relationship adjust, adapt and ... answers usually depend on who,s giving them, and come dressed ...
... HealthDay Reporter , MONDAY, Aug. 30 (HealthDay News) -- ... to rise and steps are needed to reverse the trend, ... rate of cesarean delivery climbed by more than 50 percent, ... by cesarean delivery," lead researcher Dr. Jun Zhang, of the ...
... the AVERROES study, seeing overwhelming evidence of the success ... with atrial fibrillation who are unsuitable for the conventional ... study. The decision came after repeated review and careful ... study leaders, principal investigator Dr. Stuart J. Connolly, chairman ...
... Reporter , MONDAY, Aug. 30 (HealthDay News) -- Drinking even ... cancer recurrence in some women, new research indicates. The ... postmenopausal or overweight or obese, the researchers noted. However, ... not linked to increased risk for all-cause death, and may ...
... Reporter , MONDAY, Aug. 30 (HealthDay News) -- Multiple sclerosis ... new research shows. In a study using MRI scans ... and Women,s Hospital in Boston found that new lesions occurred ... summer compared to colder times of the year. "We ...
Cached Medicine News:Health News:Diverse diet of veggies may decrease lung cancer risk 2Health News:Children raised by gay couples show good progress through school 2Health News:Children raised by gay couples show good progress through school 3Health News:Almost 1 in 3 First-Time Deliveries Now Via C-Section 2Health News:Almost 1 in 3 First-Time Deliveries Now Via C-Section 3Health News:Almost 1 in 3 First-Time Deliveries Now Via C-Section 4Health News:Success stops drug trial 2Health News:Success stops drug trial 3Health News:Moderate Drinking May Boost Risk of Breast Cancer's Return 2Health News:Moderate Drinking May Boost Risk of Breast Cancer's Return 3Health News:Multiple Sclerosis Changes With the Seasons 2Health News:Multiple Sclerosis Changes With the Seasons 3
The REVEALRT and REVEALXVI PET/CT scanners combine our fastest PET scanner, the REVEALXL, with multi-slice spiral CT scanners from Siemens Medical Systems....
... a second generation device, having evolved from ... over 700 patients beginning in 1989. Designed ... cardiologists who perform these procedures, CardioSEAL has ... the engineering bench, and in animals. In ...
Allows surgeons to successfully complete coronary artery bypass without cross clamping or side biting. Saphaneous vein grafts may be attached to the aorta without sutures....
... treat a diverse range of patients suffering ... retinal disease. Compact, Space Saving Design - ... health care professionals to use the system ... Water-cooled: The power consumption is saved by ...
Medicine Products: